Summary
In 18 healthy volunteers, in a double-blind placebo-controlled study, we investigated of whether 14 days treatment with a therapeutic dose of ibopamine (3×100 mg/day p.o.), respectively its active metabolite epinine, would desensitize lymphocyte β2- or platelet α2-adrenoceptors, or α1- and β-adrenoceptor mediated (phenylephrine-and isoprenaline infusions, respectively), changes in systolic and diastolic blood pressure and heart rate.
Ibopamine-treatment, which resulted in peak plasma epinine concentrations of 4–5 nmol·l−1, neither affected resting heart rate or blood pressure, nor any of the α- or β-adrenoceptor parameters measured. Since in man in general long-term administration of α- and β-adrenoceptor agonists desensitizes α- and β-adrenoceptors, the lack of any α- and β-adrenoceptor desensitizing effect of ibopamine suggests that, in the dose employed (3×100 mg per day), ibopamine does not exert α- or β-adrenoceptor agonistic effect in humans.
This is a preview of subscription content, log in via an institution to check access.
References
Henwood JM, Todd PA (1989) Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 36: 11–31
Taylor SH (1989) Pharmacotherapeutic profile of ibopamine in heart failure. J Cardiovasc Pharmacol 14 (Suppl. 8): S118-S123
Semeraro C, Ferrini R, Allievi L, Pocchiari F, Nicosia S, Casagrande C (1990) Peripheral vascular and neuronal effects of dopamine receptor agonists. A comparison with receptor binding studies in rat striatum. Naunyn-Schmiedeberg's Arch Pharmacol 342: 539–546
Brodde O-E (1990) Physiology and pharmacology of cardiovascular catecholamine receptors: implications for treatment of chronic heart failure. Am Heart J 120: 1565–1572
Deighton NM, Motomura S, Bals S, Zerkowski H-R, Brodde O-E (1992) Characterization of the beta adrenocpetor subtype(s) mediating the positive inotropic effects of epinine, dopamine, dobutamine, denopamine and xamoterol in isolated human right atrium. J Pharmacol Exp Ther 262: 532–538
Nichols AJ, Ruffolo RR (1987) Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine. J Pharmacol Exp Ther 242: 455–463
Lang R, Schäfer H, Scollar P, Fischer H, Bernards P (1989) Variabilität der adrenergen Rezeptoren während Langzeitbehandlung mit Ibopamin bei herzinsuffizienten Patienten NYHA II–III. Herz/Kreislauf 21: 34–38
Brodde O-E, Anlauf M, Graben N, Bock KD (1982) In Vitro and In Vivo down-regulation of human platelet α2-adrenoceptors by clonidine. Eur J Clin Pharmacol 23: 403–409
Brodde O-E, Bock KD (1984) Changes in platelet alpha2-adrenoceptors in human phaeochromocytoma. Eur J Clin Pharmacol 26: 265–267
Brodde O-E, Brinkmann M, Schemuth R, O'Hara N, Daul A (1985) Terbutaline-induced desensitization of human lymphocyte β2-adrenoceptors. Accelerated restoration of β-adrenoceptor responsiveness by prednisone and ketotifen. J Clin Invest 76: 1096–1101
Brodde O-E, Daul A, Michel-Reher M, Boomsma F, Man in't Veld AJ, Schlieper P, Michel MC (1990) Agonist-induced desensitization of β-adrenoceptor function in humans. Subtype-selective reduction in β1- or β2-adrenoceptor-mediated physiological effects by xamoterol or procaterol. Circulation 81: 914–921
Brodde O-E, Petrasch S, Bauch H-J, Daul A, Gnadt M, Oefler D, Michel MC (1992) Terbutaline-induced desensitization of β2-adrenoceptor in vivo function in humans: attenuation by ketotifen. J Cardiovasc Pharmacol 20: 434–439
Daul AE, Wang XL, Michel MC, Brodde O-E (1987) Arterial hypotension in chronic hemodialyzed patients. Kidney Int 32: 728–735
Elliott HL, Sumner DJ, McLean K, Reid JL (1982) Effect of age on the responsiveness of vascular α-adrenoceptors in man. J Cardiovasc Pharmacol 4: 388–392
Arnold JMO, O'Connor PC, Riddell JG, Harron DWG, Shanks RG, McDevitt DG (1985) Effects of the β2-adrenoceptor antagonist ICI 118, 551 on exercise tachycardia and isoprenaline-induced β-adrenoceptor responses in man. Br J Clin Pharmacol 19: 619–630
Vincent HH, Man in't Veld AJ, Boomsma F, Derkx FHM, Schalekamp MADH (1987) Is β1-antagonism essential for the antihypertensive action of β-blockers? Hypertension 9: 198–203
Brodde O-E, Daul A, Wellstein A, Palm D, Michel MC, Beckeringh JJ (1988) Differentiation of β1-and β2-adrenoceptor-mediated effects in humans. Am J Physiol 254: H199-H206
Motomura S, Zerkowski H-R, Daul A, Brodde O-E (1990) On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am Heart J 119: 608–619
Brown JE, McLeod AA, Shand DG (1986) In support of cardiac beta2 adrenoceptors. Am J Cardiol 57: 11F-16F
Brodde O-E, Hardung A, Ebel H, Bock KD (1982) GTP regulates binding of agonists to α2-adrenergic receptors in human platelets. Arch Int Pharmacodyn Ther 258: 193–207
Boomsma F, Alberts G, van der Hoorn FAJ, Man in't Veld AJ, Schalekamp MADH (1992) Simultaneous determination of free catecholamines and epinine and estimation of total epinine and dopamine in plasma and urine by high-performance liquid chromatography with fluorometric detection. J Chromatography 574: 109–117
Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672
Brodde O-E (1991) β1- and β2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brodde, O.E., Klusmann, I., Wojcik, M. et al. Lack of desensitization of α-and β-adrenoceptor function during chronic treatment of healthy volunteers with ibopamine, an orally active dopamine receptor agonist. Eur J Clin Pharmacol 44, 283–286 (1993). https://doi.org/10.1007/BF00271373
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00271373